NCT06221241View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain

PHASE2RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

March 14, 2025

Study Completion Date

April 30, 2025

Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
DRUG

JMKX000623

tablets for oral administration.

DRUG

Pregabalin

capsules for oral administration.

DRUG

Placebo

matched to JMKX000623 and Pregabalin

Trial Locations (1)

100034

RECRUITING

Peking University First Hospital, Beijing

Sponsors

Lead Sponsor

Jemincare
All Listed Sponsors
lead

Jemincare

INDUSTRY

NCT06221241 - Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain | Biotech Hunter | Biotech Hunter